You Position: Home > Paper

Belimumab: targeted therapy for systemic lupus erythematosus

( views:0, downloads:0 )
Author:
No author available
Journal Title:
International Journal of Dermatology and Venereology
Issue:
6
DOI:
10.3760/cma.j.issn.1673-4173.2014.06.006
Key Word:
红斑狼疮,系统性;贝利木单抗;分子靶向治疗;Lupus erythematosus,systemic;Belimumab;Molecular targeted therapy

Abstract´╝Ü Systemic lupus erythematosus (SLE) is a systemic autoimmune disease,whose exact pathogenesis is not fully clear as yet.The abnormal activation of B cells plays an important role in the development of SLE,and B cell-activating factor (BAFF) is critical for the abnormal activation of B cells.Belimumab is a human monoclonal antibody which can selectively recognize and block soluble BAFF.The efficacy and safety of belimumab have been confirmed for the treatment of SLE in randomized,double-blind,large-scale clinical trials.As a biological agent with high efficacy,few side effects and high tolerability,belimumab is a promising drug for SLE.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn